Mark van Duin
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
- Hematology 56
- Multiple Myeloma Research and Treatments 56
-
- Protein Degradation and Inhibitors 24
- Ubiquitin and proteasome pathways 11
- Co-authors
- Pieter Sonneveld (55 shared papers)Kenneth C. Anderson (2 shared papers)Francesca Gay (9 shared papers)S. Vincent Rajkumar (1 shared paper)Shaji Kumar (1 shared paper)Robert A. Kyle (1 shared paper)María‐Victoria Mateos (1 shared paper)Bronno van der Holt (22 shared papers)
- Journals
- Blood (25 papers)Leukemia (3 papers)Blood Advances (3 papers)Haematologica (3 papers)HemaSphere (3 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Mark van Duin
65 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Hematology 1.8k
- Oncology 1.4k
- Molecular Biology 1.9k
- Immunology 445
- Genetics 223
Countries citing papers authored by Mark van Duin
This map shows the geographic impact of Mark van Duin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark van Duin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark van Duin more than expected).
Fields of papers citing papers by Mark van Duin
This network shows the impact of papers produced by Mark van Duin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark van Duin. The network helps show where Mark van Duin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark van Duin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multiple myeloma Hit paper breakdown → | 2017 | 755 |
| 2 | 2016 | 275 | |
| 3 | 2010 | 223 | |
| 4 | 2002 | 213 | |
| 5 | 2012 | 198 | |
| 6 | 2010 | 173 | |
| 7 | 2021 | 128 | |
| 8 | 2021 | 117 | |
| 9 | Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. | 1998 | 115 |
| 10 | 2012 | 102 | |
| 11 | 1998 | 98 | |
| 12 | 2000 | 86 | |
| 13 | 2005 | 78 | |
| 14 | 2007 | 77 | |
| 15 | 2015 | 77 | |
| 16 | 2011 | 52 | |
| 17 | 2016 | 48 | |
| 18 | 2014 | 46 | |
| 19 | 2016 | 45 | |
| 20 | 2016 | 41 |
About Mark van Duin
Mark van Duin is a scholar working on Hematology, Molecular Biology, Oncology, Immunology and Epidemiology, having authored 71 papers that have together received 3.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (56 papers), Protein Degradation and Inhibitors (24 papers), Chemokine receptors and signaling (11 papers), Ubiquitin and proteasome pathways (11 papers), Peptidase Inhibition and Analysis (10 papers), Cancer Treatment and Pharmacology (6 papers), Cervical Cancer and HPV Research (6 papers) and Immunotherapy and Immune Responses (4 papers). The work is most often cited by research in Hematology (1.8k citations), Oncology (1.4k citations), Molecular Biology (1.9k citations), Immunology (445 citations) and Genetics (223 citations). Mark van Duin has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Pieter Sonneveld, Kenneth C. Anderson, Francesca Gay, S. Vincent Rajkumar, Shaji Kumar, Robert A. Kyle, María‐Victoria Mateos, Bronno van der Holt, Annemiek Broyl and Hartmut Goldschmidt. Their work appears in journals such as Blood, Leukemia, Blood Advances, Haematologica and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.